U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of ‘781 Patent Owned by Exact Sciences
29 Julio 2024 - 7:05AM
Business Wire
Geneoscopy, Inc., a life sciences company focused on developing
diagnostic tests for the advancement of gastrointestinal health,
today announced that the U.S. Patent Trial and Appeal Board (PTAB)
has instituted inter partes review (IPR) to review the
patentability of U.S. Patent No. 11,634,781 (“the ‘781 patent”)
owned by Exact Sciences.
Upon considering the petition and accompanying evidence, as well
as Exact Sciences’ response, the PTAB determined that Geneoscopy
established a reasonable likelihood that it would prevail in
showing that all 20 challenged claims of the ‘781 patent are
unpatentable. The decision can be found on the PTAB website.
“The PTAB’s decision to institute an IPR against the ‘781 patent
is a positive step for Geneoscopy,” said Andrew Barnell, CEO and
co-founder of Geneoscopy. “This ruling highlights our long-held
belief that the ‘781 patent claims are invalid and that the patent
infringement suit brought by Exact Sciences is meritless. At
Geneoscopy, we remain dedicated to expanding choice and access to
safe, effective, and convenient screening options, potentially
saving countless lives.”
Geneoscopy filed the IPR petition after Exact Sciences brought
suit in the U.S. District Court for the District of Delaware
alleging infringement of the ‘781 patent. As the petition
explained, nothing in the ‘781 patent is inventive. The claimed
method of the patent is obvious, and the claims directed to the
method are invalid. The PTAB’s decision strengthens Geneoscopy’s
defenses to the allegations in the patent lawsuit. Geneoscopy has
also filed a countersuit against Exact Sciences, alleging breach of
contract, misappropriation of trade secrets, unfair competition,
and various state and federal law violations.
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on
developing diagnostic tests for gastrointestinal health. Leveraging
its proprietary, patented stool-derived eukaryotic RNA (seRNA)
biomarker platform, Geneoscopy’s mission is to empower patients and
providers to transform gastrointestinal health through innovative
diagnostics. The company’s FDA-approved ColoSense™ test uses a
proprietary RNA-based platform to screen for colorectal cancer and
advanced adenomas for average-risk individuals over the age of 45.
In partnership with leading universities and biopharmaceutical
companies, Geneoscopy is also developing diagnostic tests for
treatment selection and therapy monitoring in other areas of
gastrointestinal health. For more information, visit
www.geneoscopy.com and follow the company on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729506584/en/
Geneoscopy Contacts: Media Andrea Sampson Sampson Public
Relations Group asampson@sampsonprgroup.com
Investor Relations Carrie Mendivil / Ji-Yon Yi Gilmartin Group
investors@geneoscopy.com